



**IM-TWIN: from Intrinsic Motivations  
to Transitional Wearable INTelligent  
companions for autism spectrum disorder**  
*a European funded project*

***Feasibility study and business model***  
**Deliverable 5.13**



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 952095.

Project duration 36 months (November 2020, October 2023).  
Consortium: Consiglio Nazionale delle Ricerche (ITA), Universiteit Utrecht (NLD), Centre de Recherches Interdisciplinaires (FRA), Università degli Studi di Roma La Sapienza (ITA), Plux-Wireless Biosignals S.A. (PRT).

## Deliverable data

<b>Work Package:</b>	5 Exploitation of IM-TWIN system
<b>Work Package leader:</b>	CNR-ISTC
<b>Deliverable beneficiary:</b>	CNR-ISTC
<b>Dissemination level:</b>	Confidential
<b>Due date:</b>	October 31 2023
<b>Type:</b>	Report
<b>Authors:</b>	Quantum Leap-Infinity Edge

## Acronyms of partners

CNR-ISTC	Consiglio Nazionale delle Ricerche, Istituto di Scienze e Tecnologie della Cognizione (Italy)
UU	Universiteit Utrecht (The Netherlands)
CRI	Centre de Recherches Interdisciplinaires (France)
LA SAPIENZA	Università degli Studi di Roma La Sapienza (Italy)
PLUX	Plux - Wireless Biosignals S.A. (Portugal)

# Table of contents

<b>1. Overview of the deliverable</b>	<b>4</b>
<b>2. Introduction</b>	<b>4</b>
<b>3. Service value chain presentation and Participantship model for the preoperational and operational phase</b>	<b>4</b>
3.1 The participantship model	5
3.2 Preoperational value chain	5
3.3 Operational value chain presentation	7
<b>4. Marketing plan</b>	<b>9</b>
4.1 Market positioning and Unique Value Proposition	9
4.2 PESTLE analysis	10
4.3 4P analysis	18
4.4 PESTLE and 4P analyses conclusions	19
4.5 Marketing strategy	20
<b>5. Economic and non-economic risks</b>	<b>23</b>
5.1 SWOT analyses	23
5.1.1 Plus-Me	23
5.1.2 IM-TWIN system	24
5.2 Regulatory barriers	24
5.2.1 US Market Requirements	24
5.2.2 EU Market Requirements	25
5.3 Patenting Limitations	28
5.4 Final remarks	29
<b>6. Financial sustainability assessment based on business case</b>	<b>30</b>
6.1 Revenues	30
6.2 Costs	31
6.3 Planned investments (CAPEX)	36
6.4 EBITDA and net profit estimate	37
6.5 Final remarks	38
<b>7. Access to funding and investment for a potential follow-on activity</b>	<b>38</b>
7.1 Service exploitation - the creation of a spin-off	39
7.2 VC Investment – Autism Spectrum Disorder	41
7.3 VC Investment – Artificial Intelligence and Wearable Technology	44
7.4 Access to funding/investment	46
<b>8. Final considerations</b>	<b>51</b>
8.1 Future developments	51
8.2 Conclusions	52

**CONFIDENTIAL**  
Only for members of the Consortium